Activated estrogen receptor‐mitogen‐activated protein kinases cross talk confer acquired resistance to lapatinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Activated estrogen receptor‐mitogen‐activated protein kinases cross talk confer acquired resistance to lapatinib

Published:2015-02-13 Issue:6 Volume:6 Page:695-703
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Li Zhe¹,Yang Sheng‐Sheng²,Yin Pei‐Hao³,Chang Tao¹,Shi Lin‐Xiang¹,Fang Lin¹,Fang Guo‐En⁴

Affiliation:

1. Department of Thyroid and Breast Surgery The Tenth People's Hospital of Shanghai Tongji University Shanghai China

2. Department of Biochemistry and Molecular Biology College of Basic Medical Sciences Second Military Medical University Shanghai China

3. Department of General Surgery Shanghai Putuo Hospital Shanghai University of Traditional Chinese Medicine Shanghai China

4. Department of General Surgery Changhai Hospital Second Military Medical University Shanghai China

Funder

National Natural Science Foundation of China

Shanghai Municipal Health Bureau

Shanghai Municipal Science and Technology Commission

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.12239

Reference28 articles.

1. Lapatinib in the treatment of breast cancer

2. Lapatinib - Overview and Current Role in Metastatic Breast Cancer

3. Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation

4. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

5. Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells;International Journal of Molecular Sciences;2024-03-09

2. Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo;Biological Procedures Online;2023-06-27

3. Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer;npj Breast Cancer;2023-05-31

4. Glutamine synthetase regulates the immune microenvironment and cancer development through the inflammatory pathway;International Journal of Medical Sciences;2023

5. Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity;International Journal of Molecular Sciences;2020-02-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3